MOTS-c: Not FDA-Approved and Should Not Be Used Clinically
MOTS-c is NOT approved by the FDA for any clinical indication and should not be prescribed or recommended for patient use. The FDA drug label evidence provided 1 refers to pravastatin (a statin medication), not MOTS-c, indicating a data error in the evidence set.
What MOTS-c Actually Is
MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA region of mitochondrial DNA 2, 3, 4. It functions as a:
- Metabolic regulator that translocates to the nucleus under stress conditions and regulates gene expression through the Folate-AICAR-AMPK pathway 2
- Mitokine with intracrine, paracrine, and endocrine effects across multiple tissues 5
- Host defense peptide with direct antibacterial and immunomodulatory properties 6
Current Status: Research Only
MOTS-c exists purely in the preclinical and early observational research phase. The available evidence consists of:
- Animal studies showing potential benefits in metabolic dysfunction, aging, cardiovascular disease, and tissue ischemia 3, 4, 7, 8
- Observational human studies measuring circulating MOTS-c levels as a biomarker in hemodialysis patients 9 and respiratory diseases 5
- Mechanistic studies in cell culture and mouse models 7, 6, 8
No randomized controlled trials in humans exist demonstrating safety or efficacy for any disease.
Critical Safety Concerns
Why You Cannot Use This Clinically:
- No FDA approval or regulatory oversight - MOTS-c is not an approved drug, biologic, or therapeutic agent
- Unknown safety profile - No Phase I, II, or III human trials establishing dosing, pharmacokinetics, or adverse effects
- No standardized formulation - Any commercially available MOTS-c would be unregulated and of unknown purity/quality
- Potential for harm - As a peptide affecting mitochondrial function, immune responses, and cellular metabolism, unapproved use carries unpredictable risks
Common Pitfall to Avoid:
Do not confuse promising preclinical research with clinical readiness. The fact that MOTS-c levels decline with age 4 and show associations with disease outcomes 9 does not mean exogenous supplementation is safe or effective in humans.
What This Means for Clinical Practice
If patients inquire about MOTS-c (often marketed online as an anti-aging or performance-enhancing peptide):
- Advise against use - Explain it is not FDA-approved and lacks human safety data
- Warn about unregulated sources - Any MOTS-c purchased online is unregulated and potentially dangerous
- Redirect to evidence-based therapies - For metabolic disease, aging, or cardiovascular concerns, use proven interventions with established safety profiles
The distinction between mitochondrial transplantation (which has limited clinical trial data in specific contexts like cardiac ischemia-reperfusion 10) and MOTS-c peptide therapy is critical - these are entirely different interventions.